Literature DB >> 36045166

Non-viral, precisely engineered immune cells tested in lymphoma.

.   

Abstract

Entities:  

Keywords:  Cancer; Drug discovery; Therapeutics

Year:  2022        PMID： 36045166     DOI： 10.1038/d41586-022-02272-z

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  5 in total

Review 1.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

2.  Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.

Authors:  Jordan Gauthier; Nicolas Gazeau; Alexandre V Hirayama; Joshua A Hill; Vicky Wu; Aisling Cearley; Paula Perkins; Angela Kirk; Mazyar Shadman; Victor A Chow; Ajay K Gopal; Alexandria Hodges Dwinal; Staci Williamson; Jessie Myers; Andy Chen; Sarah Nagle; Brandon Hayes-Lattin; Levanto Schachter; David G Maloney; Cameron J Turtle; Mohamed L Sorror; Richard T Maziarz
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

Review 3.  Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.

Authors:  Sotirios G Papageorgiou; Thomas P Thomopoulos; Athanasios Liaskas; Theodoros P Vassilakopoulos
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

4.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.

Authors:  Carolina Gándara; Valerie Affleck; Elizabeth Ann Stoll
Journal:  Hum Gene Ther Methods       Date:  2018-01-24       Impact factor: 2.396

5.  Physical principles of retroviral integration in the human genome.

Authors:  D Michieletto; M Lusic; D Marenduzzo; E Orlandini
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.